ClinicalTrials.gg
CompletedNCT01951599Updated Mar 31, 2017

To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food.

A Phase 1 interventional study of AZD9291 and AZD9291 in Healthy Volunteers, sponsored by AstraZeneca. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-31.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

To determine the relative bioavailability of different oral formulations of AZD9291 and the effect of food in healthy volunteers.

Read the detailed description

A Phase I, Open-label, Single-center, Sequential Design Study in Healthy Volunteers to Determine the Relative Bioavailability of Different Oral Formulations of AZD9291 and the Effect of Food

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Phase I, healthy, bioavailability, pharmacokinetics, safety, tolerability.
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1, between 19 and 30 kg/m2 and weight at least 50 kg and no more than 100 kg. 2, Volunteers must be willing to use a condom, unless their partners are , surgically sterile, or using an effective hormonal method of or intrauterine coil. 3. In addition, volunteers must agree to continue to take similar contraceptive precautions until 4 months after the last dose of AZD9291.

Exclusion criteria

Exclusion Criteria:

  1. Any abnormalities in physical examination, vital signs, hematology, clinical chemistry, urinalysis or at baseline in the opinion of the Investigator.
  2. Volunteers who have received live or in the 2 weeks prior to dosing.
  3. History of severe allergy/ or or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to AZD9291, its , or drugs with a similar chemical structure or class.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    AZD9291 20mg (oral capsule fasted)

    Volunteers will receive AZD9291 20mg administered by mouth, as a capsule, in the fasted state.

    Drug: AZD9291

  • Experimental
    AZD9291 20mg (oral solution fasted)

    Volunteers will receive AZD9291 20mg administered by mouth, as a solution, in the fasted state.

    Drug: AZD9291

  • Experimental
    AZD9291 20mg (oral tablet fasted)

    Volunteers will receive AZD9291 20mg administered by mouth, as a tablet, in the fasted state.

    Drug: AZD9291

  • Experimental
    AZD9291 20mg (oral fasted)

    Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fasted state.

    Drug: AZD9291

  • Experimental
    AZD9291 20mg (oral fed)

    Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fed state.

    Drug: AZD9291

Interventions

  • Volunteers will receive a single 20-mg dose of AZD9291 as a capsule on day 1, in Part A, Period 1, in the fasted state. (Treatment A).

  • Volunteers will receive a single 20-mg dose of AZD9291 as a solution on day 1, in Part A, Period 2, in the fasted state. (Treatment B).

  • Volunteers will receive a single 20-mg dose of AZD9291 as a tablet on day 1, in Part A, Period 3, in the fasted state. (Treatment C).

  • Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 1, in the fasted state.

  • Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 2, in the fed state.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of AZD9291 and its metabolites, by assessment of maximum plasma concentration (Cmax)

    Curve taken during each of the 5 treatments

    Time frame: Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose

Secondary outcomes

  1. Pharmacokinetics of AZD9291 and its metabolites by assessment of the area under the plasma concentration-time curve from zero to infinity (AUC)

    Curve taken during each of the 5 treatments

    Time frame: Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose

  2. Pharmacokinetics of AZD9291 and its metabolites, by assessment of time to Cmax (tmax)

    Curve taken during each of the 5 treatments

    Time frame: Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose

  3. Pharmacokinetics of AZD9291 and its metabolites, by assessment of Terminal rate constant (λz)

    Curve taken during each of the 5 treatments

    Time frame: Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose

  4. Pharmacokinetics of AZD9291 and its metabolites, by assessment of Terminal half life (t1/2,λz)

    Curve taken during each of the 5 treatments

    Time frame: Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose

  5. Pharmacokinetics of AZD9291 and its metabolites, by assessment of lag time before observation of quantifiable analyte concentrations in plasma (tlag)

    Curve taken during each of the 5 treatments

    Time frame: Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose

  6. Pharmacokinetics of AZD9291 and its metabolites, by assessment of area under the plasma concentration-time curve from zero to time of last measurable concentration [AUC(0-t)]

    Curve taken during each of the 5 treatments

    Time frame: Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose

  7. Pharmacokinetics of AZD9291 and its metabolites, by assessment of area under the plasma concentration-time curve from zero to 72 hours [AUC(0-72)]

    Curve taken during each of the 5 treatments

    Time frame: Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose

  8. Pharmacokinetics of AZD9291 only, by assessment of apparent plasma clearance (CL/F).

    Curve taken during each of the 5 treatments

    Time frame: Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose

  9. Pharmacokinetics of AZD9291 only, apparent volume of distribution (Vz/F)

    Curve taken during each of the 5 treatments

    Time frame: Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose

  10. Pharmacokinetics of AZD9291 parent to metabolite ratio (calculated for both Cmax and AUC).

    Curve taken during each of the 5 treatments

    Time frame: Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose

Other outcomes

  1. Safety variables (adverse events, physical exam, vital signs, ECG's, clinical laboratory safety tests, opthalmological examination)

    Assessments performed during each of the 5 treatments.

    Time frame: Baseline (Day-1) to Day 28

07

Study locations

1 site
  • Research Site
    Overland Park, Kansas, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2013 to primary completion in Jun 2014, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2013
First posted
Sep 26, 2013
StartActual
Oct 9, 2013
Primary completionActual
Jun 4, 2014
CompletionActual
Jun 4, 2014
Last update
Mar 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01951599
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 26, 2013
Start date
Oct 9, 2013
Primary completion
Jun 4, 2014
Completion
Jun 4, 2014
Last update
Mar 31, 2017

Study contacts

Phil Leese, MD
principal investigator · Quintiles 6700 W 115th Street, Kansas, US

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion